Healthcare Industry News:  adrenomyeloneuropathy 

Biopharmaceuticals Personnel

 News Release - February 11, 2010

Nutra Pharma Hires David Isserman as Chief Marketing Officer

Mr. Isserman, a Longtime Consultant to the Company, Will Be Responsible for Overseeing the Company’s Corporate Communications and Investor Relations

PLANTATION, Fla.--(HSMN NewsFeed)--Nutra Pharma Corp. (OTCBB: NPHC ), a biotechnology company that is developing treatments for adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has hired David Isserman to serve as its Chief Marketing Officer.

“We are thrilled to welcome David to our executive management team as Chief Marketing Officer,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “David’s extensive knowledge and experience in marketing communications and his work within the biotechnology industry will serve as tremendous assets to Nutra Pharma as we build our presence within the investment and scientific communities and as we extend the global reach of our drug brands, including Cobroxin and Nyloxin,” he added.

Mr. Isserman, a longtime consultant to the Company, will be responsible for overseeing the Company’s corporate communications and investor relations and will work directly with Nutra Pharma licensees to coordinate ongoing marketing and outreach initiatives for the Company’s drug pipeline, including its recently launched pain relievers, Cobroxin and Nyloxin.

“It has been a pleasure working with Nutra Pharma in a consulting role for the past several years and I am excited to now join the Company in an official capacity as its Chief Marketing Officer,” commented David Isserman. “I look forward to continuing to build awareness about Nutra Pharma, our recently launched pain relievers, Cobroxin and Nyloxin, and our important work developing novel treatments for neurologic and autoimmune disorders,” he said.

Prior to Joining Nutra Pharma, Mr. Isserman served as President of Isserman Consulting, a boutique marketing communications consultancy that advised early-stage biotechnology, consumer products and technology companies, and was a co-founder of RareShare, a website developed to connect patients and healthcare providers affected by rare medical disorders. Over the past several years, Mr. Isserman has served on several scientific and environmental non-profit boards and currently serves as a Trustee for the Academy of Science of St. Louis. Mr. Isserman received his Master of Business Administration (MBA) from Columbia Business School in New York.

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company’s wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena that it investigates about possibly acquiring or establishing strategic partnerships with.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above statements pertaining to the hiring of David Isserman as Chief Marketing Officer should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Source: Nutra Pharma

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.